Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-5700 Phase 1 for Zika
NCT02809443Phase 1Completed
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Prophylactic Vaccines, Antisense DNA, Small Interfering RNA (siRNA)
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of GLS-5700 in Zika virus infection (2 arms), sponsored by GeneOne Life Science, Inc. Primary endpoint: Serious Adverse Events. Started Jul 2016; status: completed.
02
Drugs
GLS-5700
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT02809443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02809443.